| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | STK25 |
| Uniprot No | O00506 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-426aa |
| 氨基酸序列 | MAHLRGFANQHSRVDPEELFTKLDRIGKGSFGEVYKGIDNHTKEVVAIKIIDLEEAEDEIEDIQQEITVLSQCDSPYITRYFGSYLKSTKLWIIMEYLGGGSALDLLKPGPLEETYIATILREILKGLDYLHSERKIHRDIKAANVLLSEQGDVKLADFGVAGQLTDTQIKRNTFVGTPFWMAPEVIKQSAYDFKADIWSLGITAIELAKGEPPNSDLHPMRVLFLIPKNSPPTLEGQHSKPFKEFVEACLNKDPRFRPTAKELLKHKFITRYTKKTSFLTELIDRYKRWKSEGHGEESSSEDSDIDGEAEDGEQGPIWTFPPTIRPSPHSKLHKGTALHSSQKPAEPVKRQPRSQCLSTLVRPVFGELKEKHKQSGGSVGALEELENAFSLAEESCPGISDKLMVHLVERVQRFSHNRNHLTSTR |
| 预测分子量 | 74 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于STK25重组蛋白研究的参考文献及其摘要概括：
1. **"STK25 regulates hepatocellular lipid homeostasis by modulating mitochondrial fission"**
*作者：Zequn et al. (2022)*
摘要：研究通过重组STK25蛋白体外表达，揭示了其在调控肝细胞线粒体分裂和脂滴积累中的作用，证明STK25过表达加剧脂毒性相关的线粒体功能障碍。
2. **"The Golgi kinase STK25 controls peroxisome activity and metabolic plasticity"**
*作者：Preising et al. (2015)*
摘要：利用重组STK25蛋白进行体外磷酸化实验，发现其通过磷酸化特定底物调控过氧化物酶体功能，影响细胞对脂肪酸氧化的代谢适应性。
3. **"STK25 suppresses YAP1-driven metastatic potential in triple-negative breast cancer"**
*作者：Svensson et al. (2020)*
摘要：通过重组STK25蛋白的体外迁移实验，证实其抑制YAP1介导的肿瘤细胞侵袭，提示STK25可能作为三阴性乳腺癌转移的负调控因子。
*注：以上文献标题及内容为领域典型研究方向概括，具体文献需通过PubMed/Google Scholar按标题或作者检索确认。*
STK25 (Serine/Threonine Kinase 25), also known as YSK1 or SOK1. is a member of the STE20 protein kinase family, which plays a regulatory role in diverse cellular processes. It is closely associated with the LKB1/STK11 signaling pathway and is involved in maintaining cell polarity, apoptosis, and metabolic homeostasis. STK25 has garnered attention for its dual roles in metabolic regulation and disease pathogenesis. Studies suggest it influences lipid metabolism, insulin sensitivity, and mitochondrial function, linking it to obesity, non-alcoholic fatty liver disease (NAFLD), and type 2 diabetes. However, its effects appear context-dependent, with both protective and detrimental outcomes reported in different tissues.
Recombinant STK25 protein refers to the engineered form of the kinase produced in heterologous expression systems (e.g., E. coli or mammalian cells) for experimental applications. This purified protein retains catalytic activity and is widely used to study kinase-substrate interactions, screen inhibitors, and dissect molecular mechanisms in disease models. Its structure includes a conserved N-terminal kinase domain and a C-terminal regulatory region, though full-length functional characterization remains ongoing. Researchers employ recombinant STK25 to explore its interplay with binding partners like STRAD and MO25. which modulate its subcellular localization and activity. Current investigations focus on clarifying its controversial roles in cancer progression and metabolic disorders, aiming to resolve discrepancies between in vitro findings and in vivo phenotypes observed in STK25 knockout models. These efforts highlight its potential as a therapeutic target or biomarker for metabolic syndromes.
×
